Terrance Gregg

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA.

Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Ocular Sciences, Inc. was manufacturer and marketer of contact lenses for annual and disposable replacement regimens. It used to manufacture soft contact lenses such as disposable toric, cosmetic, aspheric, multi-focal, sports and extended-wear lenses. Ocular sciences was marketing their products exclusively to eye care practitioners, both in private practice and retail chains. The company was founded in 1983 and was headquartered in Concord, CA.

The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Part of Halma Plc, LMS Medical Systems Ltd develops monitoring software for medical uses. The private company is based in Montréal, Canada. The Canadian company was founded by James W. G. Turner. LMS Medical Systems was acquired by Maclos Capital, Inc. on April 01, 2004.